Oxygenta Pharmaceutical (524636) Q2 24/25 earnings summary

Executive summary

• Un-audited financial results for the quarter and half-year ended September 30, 2024, were approved and reviewed by the Board and statutory auditors.

• The company operates solely in the manufacturing of pharmaceutical products.

Financial highlights

• Total income from operations for Q2 FY25 was ₹1,475.45 lakhs, up from ₹1,307.71 lakhs in Q2 FY24.

• Net loss for Q2 FY25 stood at ₹285.39 lakhs, compared to a net loss of ₹316.00 lakhs in Q2 FY24.

• Loss before tax for Q2 FY25 was ₹277.34 lakhs, an improvement from ₹317.99 lakhs loss in Q2 FY24.

• EPS (basic) for Q2 FY25 was (₹0.81), compared to (₹0.87) in Q2 FY24.

Outlook and guidance

• The company is prioritizing compliance and transparency, especially regarding statutory obligations and MSME creditor identification.